Management of T3 Invasive Mucinous Adenocarcinoma of the Appendix

Surgical Management

Completion right hemicolectomy is recommended for T3 tumors to obtain an adequate lymph node harvest (minimum 12 nodes) and to achieve wide en‑bloc resection of colon and mesentery, which is essential for accurate staging between stage II and stage III. 1
Nodal metastases are identified in approximately 20 % of patients with T3 mucinous adenocarcinoma, underscoring the need for systematic lymphadenectomy. 2

Presence of lymphovascular invasion is a high‑risk feature that increases the likelihood of recurrence and guides the decision to use adjuvant chemotherapy. 2
Positive surgical margins (≤ 1 mm) mandate re‑excision to achieve oncologically adequate clearance. 2

High‑risk pathological features (lymphovascular invasion, < 12 harvested nodes, poorly differentiated histology) should prompt consideration of adjuvant chemotherapy. 1
Gastrointestinal‑type regimens such as FOLFOX or capecitabine + oxaliplatin are appropriate because mucinous appendiceal adenocarcinomas share biologic behavior with gastrointestinal tumors (NCCN). 3
Observation without chemotherapy is reasonable for well‑differentiated T3 tumors lacking high‑risk features (NCCN). 3

Adjuvant chemotherapy is recommended; either standard colorectal cancer regimens (carboplatin + paclitaxel or docetaxel) or gastrointestinal‑type regimens (FOLFOX or capecitabine + oxaliplatin) may be used (NCCN). 3

Colonoscopy should be performed at 1 year post‑resection and repeated every 3–5 years if normal (Annals of Oncology guideline). 1
Serum CEA should be measured every 3–6 months for the first 2 years, then every 6 months through years 3–5 (Annals of Oncology guideline). 1
Adequate lymph node harvest (≥ 12 nodes) remains a critical quality metric; failure to meet this threshold is a high‑risk factor that influences the need for adjuvant therapy. 2

Evidence level: not specified for the cited statements.